EHA2021 – Update-in-Hematology

 VIDEO   1:03:33   06/2021

Rationale and Role of BTK Inhibition as a Treatment Strategy for Patients with Indolent B-Cell Lymphomas

Background and Insights on the Use of BTK inhibitors Now and in Future in WM and MZL

 

Agenda:

SPEAKERTOPIC
Christian BuskeWelcome & Introduction
Steven TreonRationale for Targeting TLR/BCR in Indolent Lymphomas ‒
Role of BTK inhibition as a Treatment Option for WM and MZL
Shirley D’SaWM and MZL ‒ disease, diagnosis, role of TLR/BCR pathway
Christian BuskeWM ‒ SoC and Role of BTK inhibitors now and in future
Alessandra TedeschiMZL ‒ SoC and Role of BTK inhibitors now and in future
Christian BuskePanel Discussion and Audience Q&A (Live)

Rating

Rate this resource